PR Newswire Clinical TrialsOriginal article
Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist
ISM1354Positive
AI Analysis
Summary
Insilico Medicine announced the nomination of ISM1354, a next-generation small molecule GIPR antagonist, as part of the expanding weight management therapeutic market. The announcement references the significant commercial success of competing GLP-1 receptor agonist tirzepatide, which achieved $36.507 billion in annual sales in 2025.
Financial Highlights
Revenue
$36.507 billion
Outcome Details
Drug candidate nomination
Importance:4/10
Sentiment:
0.60
drug_nominationGIPR_antagonistweight_managementsmall_moleculeGLP-1_market
Read the original article
Published by PR Newswire Clinical Trials on September 30, 2026 5:57 AM